Emerging Therapies Ocrevus Relapsing Forms of Multiple Sclerosis – Wave 1 (US) – 2017

Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers potent efficacy, while its selectivity provides a safety profile that may set it apart from other highly efficacious—but risk-prone—DMTs. A competitive price offering from Genentech/Roche coupled with a clean, unrestrictive label will ease neurologists’ incorporation of Ocrevus into practice. DRG’s launch tracking series will examine how the perception and performance of Ocrevus evolves through year one in an MS market still waiting for the DMT that balances efficacy and risk better than Tysabri or Tecfidera and in a field that perennially debates the merits of early, aggressive intervention.

What you will learn in this content:

  • What is U.S. neurologists’ awareness of and familiarity with Ocrevus, and what are their perceptions of this product?
  • For which patients are neurologists prescribing Ocrevus, what are their reasons for prescribing in relapsing MS, and how satisfied are they with Ocrevus?
  • What are the promotional messages and activities that Genentech and Roche are employing in support of the Ocrevus launch in relapsing MS?
  • How does the trial and adoption of Ocrevus compare with other recent product launches in the relapsing MS market? How do adopters and nonadopters of Ocrevus in the largest MS subpopulation compare across key metrics?

Product description:

Launch Tracking: Ocrevus Wave 1 (US) Relapsing Forms of Multiple Sclerosis is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Login to access report